Kcl + Nacl Fresenius Kabi (Potassium Chloride, Sodium Chloride)

The formulation delivers potassium (K⁺) and sodium (Na⁺) directly into the circulation. Potassium restores intracellular concentrations needed for cardiac and muscular function, while sodium expands extracellular fluid volume and supports osmotic balance. Together they re‑establish normal electrolyte gradients and improve overall cellular activity.

The dose is individualized by the prescribing clinician based on the patient’s current serum potassium and sodium levels, renal function, fluid status, and the clinical situation. No fixed regimen is provided here; the prescriber calculates the appropriate volume and concentration for each case.

The pregnancy category for this product is listed as unknown. Use during pregnancy or lactation should only occur when the potential benefit justifies any potential risk, and it must be decided by the treating physician after evaluating maternal and fetal health.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if required) and any necessary import documentation.

Kcl + Nacl Fresenius Kabi combines both potassium and sodium in a single sterile injection, which can simplify therapy compared with using separate potassium‑chloride and sodium‑chloride preparations. It offers precise concentration control and is manufactured under EU GMP standards, making it comparable to other high‑quality electrolyte blends used in intensive‑care settings.

The product should be stored at 2‑8 °C in a refrigerator, protected from light. Do not freeze or shake the vial. Before use, inspect for particulate matter or discoloration and allow the solution to reach room temperature if required by the administration protocol.

It is given intravenously, typically by slow infusion through a peripheral or central line. The rate and total volume are determined by the prescriber according to the patient’s electrolyte deficits, cardiac status and overall fluid balance. Continuous monitoring of vital signs and serum electrolytes is recommended during administration.

The most critical risks include severe hyperkalemia, which can cause life‑threatening cardiac arrhythmias, and severe hypernatremia leading to neurologic complications. Anaphylactic reactions, although rare, are also serious. Prompt recognition of symptoms such as chest pain, palpitations, sudden weakness, or allergic signs should trigger immediate medical intervention.

Patients with known hypersensitivity to potassium chloride, sodium chloride, or any excipients in the formulation should avoid this product. It is also contraindicated in individuals with uncontrolled hyperkalemia, severe renal failure without dialysis, or conditions where rapid sodium loading could worsen fluid overload, unless closely monitored.